Iridium Therapeutics LLC

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Livingston, NJ, dedicated to the discovery and development of innovative products for cancer patients. With a focus on disrupting specific cellular pathways crucial for cancer cell proliferation, Onconova is developing proprietary targeted anti-cancer agents. Their pipeline includes the multi-kinase inhibitor narazaciclib ON 123300, currently undergoing Phase 1 studies in the United States and China, and the product candidate oral rigosertib, being investigated as a single agent therapy for RDEB-associated squamous cell carcinoma and in combination with PD1 checkpoint inhibitors in IO-refractory KRAS mutated non-small cell lung cancer and malignant melanoma. Founded in 1998 and publicly traded on the NASDAQ stock exchange under the ticker symbol ONTX since July 2013, Onconova Therapeutics is committed to advancing the field of oncology through its cutting-edge research and development efforts. With a strong leadership team, board of directors, and scientific advisory board, the company is dedicated to bringing novel cancer treatments to patients in need.Generated from the website